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FIGHTING FOR YOUR LIFE IN AMERICA:
A STUDY OF “RIGHT TO TRY” LAWS
THROUGHOUT THE COUNTRY
DANIELLE DELGROSSO†
INTRODUCTION
On June 9, 2011, cancer took the life of twenty-one-year-old
Abigail Burroughs.1 Abigail spent the final seven months of her
life fighting for access to an experimental drug, Erbutrix, not yet
approved by the Food and Drug Administration (“FDA”) that her
treating physician and family believed could save her life.2 Her
efforts were unsuccessful.3
Abigail’s death spawned the Abigail Alliance, a non-profit
advocacy organization working for FDA regulatory changes that
would allow terminally ill patients access to experimental drugs.4
Spear-headed by Abigail’s father, Frank Burroughs,5 the Alliance
has made noise in the media,6 in the courtroom,7 and on Capitol
Hill.8 The commotion prompted “Right to Try” legislation to be

†
Notes & Comments Editor, St. John’s Law Review; J.D. Candidate, 2018, St.
John’s University School of Law; B.A. English Literature, 2014, University of North
Carolina at Wilmington. With thanks to Professor Anita S. Krishnakumar for her
guidance and support in writing this Note, Professor Heather M. Butts for her
mentorship, and the entire St. John’s Law Review editorial board for its dedication
during this process.
1
Frank Burroughs, Our Story, ABIGAIL ALLIANCE, http://www.abigail-alliance.o
rg/story.php (last visited Dec. 27, 2017).
2
Sue Kovach, The Abigail Alliance: Motivated by Tragic Circumstances,
Families Battle an Uncaring Bureaucracy, LIFE EXTENSION 26 (2007), http://www.ab
igail-alliance.org/LEMSEP07pAbigailLR.pdf.
3
Id.
4
Id. For purposes of this Note, the term “experimental drug[s]” refers to
experimental drugs, biological products, or devices.
5
Burroughs, supra note 1.
6
See Kovach, supra note 2, at 30.
7
See Abigail All. for Better Access to Developmental Drugs v. Von Eschenbach,
495 F.3d 695 (D.C. Cir. 2007).
8
Kovach, supra note 2, at 29.
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passed in thirty-two states,9 and proposed in sixteen others.10 In
May of 2016, a federal “Right to Try” bill was proposed in
Congress.11 Problematically, not all of these laws look the same.
Congress’s bill, the Trickett Wendler Right to Try Act of 2016
(“the Trickett Wendler Act”),12 is named after a young mother of
three who lost her battle against Amyotrophic Lateral Sclerosis
(“ALS”) in March of 2015.13 Trickett and Abigail have similar
stories. Both suffered from conditions that would ultimately take
their lives,14 were treated with drugs that could not and did not
save them,15 and were denied access to unapproved drugs.16 Had
the Trickett Wendler Act been law while Trickett or Abigail were
alive, their stories may have had different endings.
This Note argues that there should be a federal statute
granting terminally ill patients access to experimental drugs, but
that the Trickett Wendler Act, as written is not the proper
vehicle for change. An ideal congressional “Right to Try” statute
9
Lenore Skenazy, Opinion, The Dying Deserve a Last Chance at Life,
TIMESLEDGER NEWSPAPERS, Dec. 22, 2016.
10
Editorial, Right-to-Try, COURIER (Northwestern Ohio) (Dec. 14, 2016), http://
thecourier.com/opinion/couriers-view/2016/12/14/right-to-try/.
11
See S. 2912, 114th Cong. (2016); see also Trickett Wendler Right to Try Act of
2016, CONGRESS.GOV, https://www.congress.gov/bill/114th-congress/senate-bill/2912
?q=%7B%22search%22%3A%5B%22s+2912%22%5D%7D&r=1 (last visited Dec. 27,
2017).
12
S. 2912 114th Cong. (2016). In January 2017, a revised version of S.2912 was
introduced in and subsequently passed by the Senate. See S. 204, 115th Cong. (2017)
(The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina
Right to Try Act of 2017). In February, 2017, yet another version was introduced in
the House. See H.R. 878, 115th Cong. (2017) (Right to Try Act of 2017). While this
Note focuses exclusively on S. 2912, its analysis applies to all versions.
13
Jenna Sachs, Fighting for the “Right to Try:” 14 Months After Her Death from
ALS, Trickett Wendler’s Legacy Taking Shape, FOX6 NEWS (MILWAUKEE) (May 17,
2016, 9:56 PM), http://fox6now.com/2016/05/17/fighting-for-the-right-to-try-14-month
s-after-her-death-from-als-trickett-wendlers-legacy-taking-shape/.
14
Id. (“ALS has no treatment, no cure, no survivors . . . .”); Sean Alfano,
Fighting for a Miracle, CBS NEWS (Nov. 13, 2005, 3:26 AM), http://www.cbsnew
s.com/news/fighting-for-a-miracle/ (reporting that Abigail knew early that her
situation was hopeless).
15
Joseph Gulfo, A Hearing Brought to Tears over Right to Try Legislation, THE
HILL (May 17, 2016, 7:00 AM), http://thehill.com/blogs/pundits-blog/healthcare/2801
27-a-hearing-brought-to-tears-over-right-to-try-legislation (explaining that Trickett’s
current treatment would slow the process of her disease, but would not cure it);
Burroughs, supra note 1 (stating that Abigail had run out of conventional options).
16
Ann-Elise Henzl, Terminally Ill Patients and Their Loved Ones Push for
Greater Access to Experimental Drugs, UW-MILWAUKEE: MILWAUKEE PUBLIC MEDIA
(May 11, 2016), http://wuwm.com/post/terminally-ill-patients-and-their-loved-onespush-greater-access-experimental-drugs#stream/0; see also Burroughs, supra note 1.
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should be crafted to make experimental drugs realistically
obtainable for terminally ill patients while protecting those
patients and their quality of life. The Trickett Wendler Act’s
weaknesses prevent it from reaching this objective because it is
too deferential to already unclear state Right to Try laws. Part I
explores the right to try movement generally, explaining what a
“right to try” is and the obstacles currently standing in its way.
Part II examines and critiques different “Right to Try” laws that
have been adopted in the states. Part III proposes a model
congressional “Right to Try” bill.
I.

THE RIGHT TO TRY

Essentially, “Right to Try” laws provide terminally ill
patients with access to experimental treatments that have
successfully passed the first of the FDA’s three phases of clinical
trials.17 According to FDA guidelines, a drug normally cannot go
to market until it has successfully passed a phase-three trial.18 It
is only at this point that the drug is considered safe and effective
for human consumption.19 Right to Try laws effectively bypass
the FDA’s system, allowing access to a drug before it receives the
FDA’s stamp of approval.20 Right to Try proponents say this will
reduce terminal patients’ waiting time for drugs not yet
approved21—time that they simply do not have.

17

CHRISTINA CORIERI, GOLDWATER INST., EVERYONE DESERVES THE RIGHT TO
TRY: EMPOWERING THE TERMINALLY ILL TO TAKE CONTROL OF THEIR TREATMENT 1
(Feb. 11, 2014), https://goldwater-media.s3.amazonaws.com/cms_page_media/2015/1/
28/Right%20To%20Try.pdf; Kimberly Leonard, Seeking the Right to Try, U.S. NEWS
(Nov. 18, 2014, 12:01 AM), http://www.usnews.com/news/articles/2014/11/18/right-totry-laws-allowing-patients-to-try-experimental-drugs-bypass-fda.
18
The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/drugs/resourcesforyou/consumers/ucm
143534.htm (last updated Nov. 24, 2017) [hereinafter FDA Drug Review Process];
Conducting Clinical Trials, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/drugs
/developmentapprovalprocess/conductingclinicaltrials/default.htm
(last updated
June 15, 2016) (“Clinical trials are an integral part of new product discovery and
development and are required by the Food and Drug Administration before a new
product can be brought to the market.”).
19
FDA Drug Review Process, supra note 18.
20
Leonard, supra note 17.
21
Matthew Bellina, FDA Should Allow Treatment of Terminally Ill Patients
with Experimental Drugs, WASH. POST: POWER POST (Sep. 28, 2016, 10:17 AM),
https://www.washingtonpost.com/news/powerpost/wp/2016/09/28/fda-should-allowtreatment-of-terminally-ill-patients-with-experimentaldrugs/?utm_term=.1d7591d80ec4.

FINAL_DELGROSSO

746

3/25/2018 7:33 PM

ST. JOHN’S LAW REVIEW

[Vol. 91:743

State Right to Try laws embrace the belief that it is a
terminally ill patient’s fundamental right to access unapproved
drugs.22 At the heart of that belief is the idea that a person has
the fundamental right to try to save his or her own life.23
Advocates’ bottom line is that individuals should not have to ask
the government for permission to survive.24
However, there are three chief obstacles to Right to Try laws’
success: (1) there is no recognized constitutional right to try;
(2) state Right to Try laws are federally preempted by FDA
guidelines; and (3) there is no consensus as to whether a right to
try should exist.
First, despite proponents’ assertions that the terminally ill
have a fundamental right to access investigational drugs, courts
have not agreed.25 In Abigail Alliance v. Eschenbach, the United
States Court of Appeals for the District of Columbia Circuit
stated that, “such rights are not set forth in the language of the
Constitution,” and “there is no fundamental right ‘deeply rooted
in this Nation’s history and tradition’ of access to experimental
drugs for the terminally ill.”26
Second, the United States Constitution’s Supremacy Clause
disallows any state law that contravenes a federal statute or
statutorily authorized federal regulation.27 Such a state law is

22
Rebecca Dresser, The “Right to Try” Investigational Drugs: Science and
Stories in the Access Debate, 93 TEX. L. REV. 1631, 1640 (2015) (It is “the
fundamental right of people to save their own lives”) (quoting CORIERI, supra note
17, at 1).
23
Id.
24
See id.
25
Alexandra Tsakopoulos, et al., Note, The Right to Try: An Overview of Efforts
To Obtain Expedited Access to Unapproved Treatment for the Terminally Ill, 70
FOOD & DRUG L.J. 617, 620 (2015).
26
Abigail All. for Better Access to Developmental Drugs v. Von Eschenback, 495
F.3d 695, 697, 702 (D.C. Cir. 2007) (quoting Washington v. Glucksberg, 521 U.S.
702, 720–21 (1997)), cert. denied, 552 U.S. 1159 (2008). The Supreme Court, denying
certiorari, has not directly answered this question. Thus, it remains possible that
eventually the Supreme Court will opine that such a fundamental right exists. As of
today, access to experimental drugs is not considered a fundamental right.
27
U.S. CONST. art. VI, cl. 2 (“This Constitution, and the Laws of the United
States which shall be made in Pursuance thereof . . . shall be the supreme Law of
the Land; and the Judges in every State shall be bound thereby, any Thing in the
Constitution or Laws of any State to the Contrary notwithstanding.”). See also
Caitlyn Martin, Note, Questioning the “Right” in State Right to Try Laws: Assessing
the Legality and Effectiveness of These Laws, 77 OHIO ST. L.J. 159, 178 (2016) (citing
to Maryland v. Louisiana, 451 U.S. 725, 746 (1981); McCulloch v. Maryland, 17 U.S.
316, 427 (1819); City of New York v. FCC, 486 U.S. 57, 63–64 (1988)).
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preempted, or trumped, by the federal statute or regulation,
making the state law ineffective.28 Although the question of
whether or not state Right to Try laws are federally preempted
has not been answered definitively, they are most likely trumped
by FDA guidelines.
The FDA derives its authority to regulate the premarket
drug approval process from the Food, Drug, and Cosmetic Act
(“FDCA”).29 In accordance with this authority, the FDA created
its three-phase drug approval process,30 which state Right to Try
laws attempt to circumvent.31 It is not possible to comply with
both state Right to Try laws and federal regulatory requirements
simultaneously.32 Thus, although the FDCA does not contain any
express preemption provision,33 such state laws, which upset the
congressional purpose set forth in the FDCA,34 would likely be
preempted.35
For state Right to Try laws to escape federal preemption,
federal action is necessary. Although the FDA has its own
Expanded Access program to address the needs of terminally ill
patients,36 the FDA does not support Right to Try laws.37 In a

28

U.S. CONST. art. VI, cl. 2.
Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 (2012).
30
Id. § 355(D)(i)(II); see also Martin, supra note 27, at 168.
31
Emily Hogan, Note, “Right to Try” Legislation and Its Implications for the
FDA Drug Approval Process, 50 WASH. U. J.L. & POL’Y 171, 186–87 (2016).
32
21 U.S.C. § 355(a) (2012); see also Martin, supra note 27, at 163 (“A ‘direct
conflict’ exists between the FDCA and state Right to Try laws because it is
impossible for organizations to comply with both laws, and the purpose of the FDA
to regulate new drugs is undoubtedly frustrated.”).
33
21 U.S.C. § 301 (2012).
34
United States v. Article of Drug Bacto-Unidisk, 394 U.S. 784, 798 (1969)
(“[T]he Act’s overriding purpose [is] to protect the public health, and specifically,
§ 507’s purpose [is] to ensure that [drugs] marketed serve the public with ‘efficacy’
and ‘safety.’ “) (first citing United States v. Sullivan, 332 U.S. 689, 693–95 (1948);
and then citing United States v. Dotterweich, 320 U.S. 277, 283–84 (1943)).
35
Jonathan J. Darrow et al., Practical, Legal, and Ethical Issues in Expanded
Access to Investigational Drugs, 372 NEW ENG. J. MED. 279, 283 (2015). “[R]ight-totry laws are unlikely to withstand a constitutionality challenge that is based on
conflict with the FDA’s enabling legislation and existing expanded-access
regulations.” Id.
36
21 C.F.R. § 312 (2016); see also Expanded Access (Compassionate Use), U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/NewsEvents/PublicHealthFocus/Expand
edAccessCompassionateUse/default.htm (last updated Oct. 3, 2017). Unfortunately,
Right to Try law advocates do not believe that the FDA’s expanded access program is
speedy enough nor that it helps enough people. See, e.g., Bellina, supra note 21
(describing the FDA’s compassionate use program as “severely flawed”).
29
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September 2016 statement, Peter Lurie, the FDA’s Associate
Commissioner for Public Health and Analysis, stated that
“[c]linical trials remain the best option for patients wishing to
gain access to investigational products and . . . the approval
process remains the best way to assure the development of and
access to safe and effective new medical products for all
patients.”38
Although there is no fundamental right to try, and state
Right to Try laws are likely federally preempted, a congressional
statute would transcend both obstacles.39 However, right to try
opponents, and their valid concerns, complicate the passage of
such a statute.40 Two opposing arguments are particularly
powerful.
First, if experimental drugs become more readily available
outside of clinical trials, it becomes increasingly difficult to
maintain the numbers necessary to perform these trials, which
harms the public health at large.41 Phase-three trials require
anywhere from three-hundred to three-thousand participants
suffering from the disease or condition.42 Relatively few patients
enroll in trials as is.43 The three-phase clinical-trial system is
37
Exploring a Right to Try for Terminally Ill Patients: Hearing on S. 2912
Before the S. Comm. On Homeland Sec. and Gov’t Aff., 114th Cong. 5 (2016)
[hereinafter Senate Hearing] (statement of Peter Lurie, Associate Commissioner for
Public Health Strategy and Analysis, U.S. FDA).
38
Id.
39
James M. Beck, Developments in Compassionate Use and Right to Try Laws,
DRUG & DEVICE LAW (June 9, 2016), https://www.druganddevicelawblog.com/2016
/06/developments-in-compassionate-use-and-right-to-try-laws.html (explaining that
state Right to Try laws would no longer be preempted if a federal Right to Try law
was adopted.).
40
For example, Senator Ron Johnson, the Trickett Wendler Act’s sponsor,
recently went to the Senate floor to seek unanimous consent for the bill, but was
blocked by Senate Minority Leader Harry Reid, an opponent of Right to Try laws.
Johnson Fails in Bid To Hotline ‘Right to Try’ Bill Through Senate, INSIDE HEALTH
POLICY (Sept. 28, 2016), https://insidehealthpolicy.com/daily-news/johnson-fails-bidhotline-right-try-bill-through-senate. See also supra note 12
41
VICTORIA WEISFELD ET AL., PUBLIC ENGAGEMENT AND CLINICAL TRIALS: NEW
MODELS AND DISRUPTIVE TECHNOLOGIES 2 (2012) (identifying “the increasing
difficulty of recruiting and retaining an appropriate human subject population for
specific clinical trials” as a “significant problem”); see also Manik Chahal, Off-Trial
Access to Experimental Cancer Agents for the Terminally Ill: Balancing the Needs of
Individuals and Society, 36 J. MED. ETHICS 367, 368 (2010).
42
The Drug Development Process, Step 3: Clinical Research, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_
Research_Phase_Studies (last updated May 25, 2017).
43
WEISFELD ET AL., supra note 41, at 2.
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essential to determining whether experimental drugs are
sufficiently safe and effective for consumption by the general
patient population.44 Thus, if trials cannot recruit patient
volunteers, then an already lengthy process loses all efficacy and
speed, and in turn cannot serve the public as intended.45
Second, early access to a drug may cause a person more
Right to Try laws grant access to
harm than good.46
investigational drugs that have passed the first of three phases of
FDA clinical trials.47 Unfortunately, Phase One trials are small,
usually conducted on about twenty to a hundred human subjects,
and are not designed to evaluate effectiveness; the purpose is
simply to supply initial information about the drug’s adverse
effects on humans.48 About seventy percent of drugs move on to
the second phase, which provides researchers with additional
safety data.49 Although Phase Two studies are conducted on
several hundred people, they are still not considered large
enough to demonstrate whether the drug will be beneficial, as
evidenced by the fact that two more phases are conducted on up
to several thousand subjects.50
The determination of how
beneficial a drug is, is made during phase-three studies, which
demonstrate whether or not a product offers a treatment benefit
to a specific population.51

44

See 21 U.S.C.A. § 355(d) (West 2014) (requiring clinical investigations of the
safety and efficiency of a drug prior to FDA approval).
45
Senate Hearing, supra note 37 (statement of Peter Lurie, Associate
Commissioner for Public Health Strategy and Analysis, U.S. FDA) (“Enrollment in
clinical trials helps to ensure adequate protection for patients and leads to the
collection of vital data that could eventually result in FDA approval of the
investigational product.”).
46
David Gorski, The False Hope of “Right-to-Try” Metastasizes to Michigan,
SCI.-BASED MED. (July 21, 2014), https://www.sciencebasedmedicine.org/the-falsehope-of-right-to-try-metastasizes-to-michigan/ (explaining that disaster can result
when compassion gets in the way of medical decision making).
47
See COLO. REV. STAT. § 25-45-103(2) (2014) (an experimental drug is one “that
has successfully completed phase one of a clinical trial but has not yet been approved
for general use by the [FDA]”).
48
The Drug Development Process, Step 3: Clinical Research, supra note 42.
49
Id.
50
Id.
51
Id. (“Phase 3 studies provide most of the safety data. In previous studies, it is
possible that less common side effects might have gone undetected. Because these
studies are larger and longer in duration, the results are more likely to show longterm or rare side effects[.]”).
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Yet, terminal patients and their advocates remain eager to
access unapproved “miracle drugs,” believing they will save lives
if only patients could get their hands on them.52 Patients and
their advocates are thus ignoring the suffering that can come
from trying novel drugs. But, if a patient is terminal, what is the
harm in trying? One expert responds, “If there’s anything worse
than dying of a terminal illness, it’s dying of a terminal illness
and suffering unnecessary complications or pain for no
benefit[.]”53 Even patients with life-threatening diseases require
protections from unnecessary risks.54 For a federal Right to Try
law to be successful, it must address these concerns.
II. COMPARING RIGHT TO TRY LAWS
State “Right to Try” laws are new, controversial, and, most
problematically, different from one another. Inviting states with
varying views on the right to try to fill in Congress’s blanks
muddles the already shaky definition of a “right to try.” This
Part highlights several critical differences between Right to Try
laws that, without well-defined congressional intervention, will
remain problematic.
A.

Eligibility Requirements

All “Right to Try” laws include a list of criteria that a patient
must meet to become an “eligible patient” for right to try
purposes.55 Generally, a state’s eligibility list is comprised of
some combination of five conditions: (1) The patient has a
terminal illness, attested to by his or her physician; (2) The
patient has considered all other treatment options currently
52

David Gorski, “Right to Try” Laws and Dallas Buyers’ Club: Great Movie,
Terrible for Patients and Terrible Policy, SCI.-BASED MED. (Mar. 8, 2014),
https://www.sciencebasedmedicine.org/right-to-try-laws-and-dallas-buyers-club-grea
t-movie-terrible-public-policy/ (alluding to the “misperception that there are ‘miracle
drugs’ out there that we will have to wait years for because the FDA is too slow to
approve them”); see also Julie Brintnall-Karabelas et al., Improving Recruitment in
Clinical Trials: Why Eligible Participants Decline, 6 J. EMPIRICAL RES. ON HUM.
RES. ETHICS 69, 70 (2011).
53
Gorski, supra note 52.
54
Senate Hearing, supra note 37 (statement of Peter Lurie, Associate
Commissioner for Public Health Strategy and Analysis, U.S. FDA).
55
Right to Try Model Legislation, GOLDWATER INST., § 1(2)(b), https://goldwatermedia.s3.amazonaws.com/cms_page_media/2015/1/28/RIGHT%20TO%20TRY%20M
ODEL%20LEGISLATION%20%282%29_1.pdf (last visited Dec. 27, 2017); see also
POLICY SURVEILLANCE PROGRAM STAFF, RIGHT TO TRY LAWS 1 (Oct. 2016).
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approved by the FDA; (3) The patient has received a
recommendation from his or her physician for the investigational
treatment sought; (4) The patient has given written, informed
consent for the use of the investigational treatment; and (5) The
patient has documentation from his or her physician that he or
she meets all of the eligibility requirements.56
Two of these requirements have been adopted by all states
with Right to Try laws. The first is requirement number two,
that the patient has considered all other currently approved
treatment options.57 This is also a necessary requirement to be
eligible for the FDA’s Expanded Access program.58
This
requirement aligns with the very important policy interest that
the unapproved drug be a last resort option. If a patient can
receive the treatment he or she needs without having to shoulder
the potential risks of an unapproved drug, Right to Try laws need
not and should not be utilized.
The second widely adopted requirement is number four, that
the patient provide “written, informed consent for the use of the”
experimental treatment.59 A majority of states additionally
define “written, informed consent,” specifying information that
must be included in the informed consent document.60 The FDA’s
Expanded Access program also requires written, informed

56
Right to Try Model Legislation, supra note 55. The Goldwater Institute is a
pubic policy think tank that has outlined proposed Right to Try legislation. Michelle
J. Rubin & Kristin R.W. Matthews, The Impact of Right to Try Laws on Medical
Access in the United States, 66 BAKER INST. POL’Y REP. 1, 6 (2016). State Right to
Try laws are generally similar to the Goldwater Institute’s template. Id.
57
Right to Try Model Legislation, supra note 55, § 1(2)(b)(ii).
58
21 C.F.R. § 312.305(a)(1) (2016).
59
Right to Try Model Legislation, supra note 55, § 1(2)(b)(iv).
60
E.g., COLO. REV. STAT. § 25-45-103(4) (2014) (stating that “written, informed
consent” documents must, at the very least, (a) “explain[] the currently approved
products and treatments for the disease or condition from which the patient suffers;”
(b) “attest[] to the fact that the patient concurs with his or her physician” that all
currently approved treatments are inadequate; (c) define[] the specific experimental
drug; (d) “describe[] the potentially best and worst outcomes of using the
[experimental] drug . . . including the possibility that new, unanticipated, different,
or worse symptoms might result” and could precipitate death; (e) “[m]ake[] clear that
the patient’s health insurer and provider are not obligated to pay for any care or
treatments consequent to the use of the [experimental] drug”; (f) clearly state that
the patient may no longer be eligible for hospice care; (g) clearly state that the
patient may be denied in-home healthcare because of the treatment; and (h) “state[]
that the patient understands that he or she is liable for all expenses consequent to
the use of the [experimental] drug . . . unless a contract between the patient and the
manufacturer of the drug . . . states otherwise.”).
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consent and provides for what information must be included in
that document.61 This requirement reflects the state’s interest in
protecting the patient. Opponents’ concern that a desperate
patient may be lured by the idea of a miracle drug is softened
when that patient is provided with enough information to make
an informed, autonomous decision. While a patient may still
hope for a miracle, a comprehensive informed consent document
emphasizes that the drug remains unapproved, and, thus, its
outcome cannot be predicted and worse symptoms might result.
While these two requirements evoke widespread acceptance,
the first and arguably most basic requirement, that the patient
be terminally ill, lacks any single accepted definition.62 State
Right to Try laws tend to define a “terminally ill” patient in one
of three ways: (1) He or she has a disease or condition not
considered to be reversible, even with the administration of
currently approved and available treatment options; (2) He or
she has a disease or condition that, in running its normal course,
will end his or her life within a certain period of time; or (3) He or
she has a disease or condition likely to result in death or is in a
permanent state of unconsciousness from which recovery is
unlikely.63
At least seven states have taken the first approach.64 This
approach generally defines a terminal illness as “[a] progressive
disease or medical or surgical condition that (i) entails significant
functional impairment, (ii) is not considered by a treating
physician to be reversible even with administration of available

61

21 C.F.R. § 50.25(a) (2016).
See United States v. Rutherford, 442 U.S. 544, 556 (1979) (noting the
difficulties of defining terminally ill and applying that definition to patients); see
also Joanne Lynne et al., Defining the “Terminally Ill:” Insights from Support, 35
DUQ. L. REV. 311, 311–12 (1996).
63
Victoria Howard, Note, Accessing Indiana’s Right-to-Try Law: Is It Enough To
Expand Access for Terminally Ill Patients?, 14 IND. HEALTH L. REV. 267, 292–99
(2017). Only one state, Indiana, does not require that the patient’s disease or
condition be life-threatening. IND. CODE ANN. § 25-22.5-1-2.1 (West 2015) (stating
that an individual may access an experimental drug if he or she has been diagnosed
with a terminal condition or if the patient’s treating physician determines that
“there is no reasonable basis to conclude” that the experimental drug, when
administered appropriately, “poses an unreasonable and significant risk” to the
patient).
64
Alabama, Michigan, Minnesota, Montana, North Carolina, South Dakota, and
Tennessee.
62
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treatments approved by the [FDA], and (iii) will soon result in
death without life-sustaining procedures.”65 This definition is
comprised of several important components.
First, it requires that the patient’s condition causes or
involves “significant functional impairment.” No state explicitly
defines “significant functional impairment.”66 The sixth edition
of the American Medical Association’s Guides to the Evaluation of
Permanent Impairment, defines impairment as “a significant
deviation, loss, or loss of use of any body structure or function in
an individual with a health condition, disorder, or disease.”67 The
Social Security Administration defined a medically determinable
impairment as “an impairment that results from anatomical,
physiological, or psychological abnormalities that can be shown
by medically acceptable clinical and laboratory diagnostic
techniques.”68 Thus, there is no explicit determinable factor of a
“significant functional impairment.” Minnesota, one of the nine
states adopting this approach, deleted this distinction from its
definition, asserting simply that a terminal disease or condition
is one “not considered reversible” and that “will soon result in
death.”69
Despite the lack of clarity as to what exactly constitutes a
“significant functional impairment,” or if such characteristic is
necessary, it is clear that the legislators intended for the
patient’s condition to be significant enough to warrant the
extraordinary permission being granted. This cautions against
unjustified determination of an eligible “terminally ill” patient
and reinforces the idea of the right to try as a last resort.
Second, this approach requires that the disease or condition
not be reversible by current FDA approved treatments.70 Once
again, this is consistent with the intent that the law be used only
as a last resort. If a patient’s condition can be treated through
an approved option, experimenting with an unapproved drug
outside of a clinical trial is unwarrantedly risky.
65

E.g., N.C. GEN. STAT. § 90-325.1(3) (2015).
See id.
67
ROBERT D. RONDINELLI ET AL., GUIDES TO THE EVALUATION OF PERMANENT
IMPAIRMENT, 876 (6th ed. 2008).
68
Disability Evaluation Under Social Security: Part I—General Information,
SOC. SEC. ADMIN., https://www.ssa.gov/disability/professionals/bluebook/general-info
.htm (last visited Dec. 27, 2017).
69
MINN. STAT. § 151.375(2)(d) (2015).
70
See supra note 64.
66
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Third, this approach requires that the patient’s disease or
condition “will soon result in death.”71 This requirement goes to
the heart of what a terminal illness realistically is—an illness
that will take a patient’s life—and illustrates why Right to Try
laws are necessary; without them, the patient will die. The
keyword in this first approach is “soon.”
This differs from the second approach, embraced by four
states,72 which demarcates a particular period of time in which
death must be likely to occur. For example, Florida defines a
terminal illness as a condition that, in running its normal course,
will result in death “within 1 year after diagnosis.”73 Oregon
defines it as a disease or condition that, in the “physician’s
reasonable medical judgment,” will result in death within six
months.74
Conversely, at least nine states do not draw a definitive line
for the time period within which death must occur, simply
requiring that death be projected to occur soon,75 in the near
future,76 or imminently.77
Regardless of which method a state adopts, this provision
reinforces the objective that Right to Try laws be utilized only as
a last resort. While states like Florida and Oregon are stricter in
their definition of “terminally ill,” the other thirteen states that
do not demarcate a “death-by-date” allow more room for
interpretation. Still, the point remains clear—the right to try
only becomes a “right” when accompanied by a patient’s
foreseeable demise.

71

Right to Try Model Legislation, supra note 55, § 1(2)(a).
Florida, Nevada, Illinois, and Oregon.
73
FLA. STAT. ANN. § 499.025(2)(c) (West 2015).
74
H.R. 2300 § 1(9), 78th Leg. Assemb., Reg. Sess. (Or. 2015).
75
Alabama, Colorado, Maine, Michigan, Minnesota, Montana, North Carolina,
Wyoming, and Oklahoma. See e.g., COLO. REV. STAT. § 25-45-103(3) (2014)
(“ ‘Terminal Illness’ means a disease that, without life-sustaining procedures, will
soon result in death . . . .”).
76
Mississippi, Missouri, and Vermont. E.g., MISS. CODE ANN. § 41-131-1(2)(c)
(West 2016) (“ ‘Terminal illness’ means a disease that without life-sustaining
procedures will result in death in the near future . . . .”).
77
VA. CODE ANN. § 54.1-3442.1 (West 2015) (“ ‘Terminal condition’ means a
condition caused by an injury, disease, or illness, from which . . . the patient’s death
is imminent . . . .”).
72
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The third approach, adopted by at least seven states,78
includes as “terminal illness” not only parties with deathtriggering diseases, but also patients in “a state of permanent
unconsciousness from which recovery is unlikely.”79
By
expanding their definition, these states include patients who may
ordinarily not be categorized as “terminally ill,”80 but have
similarly hopeless prognoses.81
Unfortunately, having three different definitions of
“terminally ill” will ultimately result in numerous bioethical
issues for patients and physicians.82 For example, different
definitions cause similar patients across the country to receive
different levels of access to experimental drugs.83 Additionally,
physicians and patients, or physicians and patients’ family
members, might disagree over whether or not a patient is eligible
for the right to try, which might result in litigation.84
To supplement the five typical eligibility requirements, some
states have adopted their own additional eligibility requirements.
Two noteworthy requirements are (1) The patient is “unable to
participate in a clinical trial;”85 and (2) The potential risks of
using the experimental drug do not outweigh the potential
benefits.
78
Colorado, Maine, Mississippi, Missouri, North Dakota, Oklahoma, and
Wyoming.
79
COLO. REV. STAT. § 25-45-103(3) (2014).
80
See Sally J.T. Necheles, Particular Medical Conditions for Which Withdrawal
of Treatment May Be Available, 77 C.J.S. RIGHT TO DIE § 18 (2017); see also Health
ALTO
MED.
FOUND.,
Maintenance
Guidelines
Terminology,
PALO
http://www.pamf.org/preventive/AHCD-terminology.html (last visited Dec. 27, 2017)
(stating that a “[p]ersistent vegetative state” is “[n]ot normally regarded as a
terminal condition and the patient can survive for many years with medical care,
artificial fluids and nutrition”).
81
The Multi-Society Task Force on PVS, Medical Aspects of the Persistent
Vegetative State, 330 NEW ENG. J. MED. 1572, 1575–76 (1994) (explaining that
survival rates for patients in a persistent vegetative state is extremely low).
82
See Diane E. Hoffman & Anita J. Tarzian, The Role and Legal Status of
Health Care Ethics Committees in the United States, in LEGAL PERSPECTIVES IN
BIOETHICS 52 (Ana S. Iltis et al. eds., Taylor & Francis e-Library ed. 2007)
(explaining how states’ differing definitions of terminal illness present bioethical
problems).
83
Richard M. Doerflinger, Conclusion: Shaky Foundations and Slippery Slopes,
35 DUQ. L. REV. 523, 525 (1996) (stating that an arbitrary definition of “terminal
illness” raises prompt “ ‘equal protection’ claims by patients who fall just outside the
definition’s borders”).
84
See Hoffman & Tarzian, supra note 82, at 54 (explaining that physicians and
family members might have differing views on a patient’s medical prognosis).
85
OKLA. STAT. ANN. tit. 63, § 3091.2(1)(c) (West 2015).
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According to the first, a patient is only an “eligible patient”
for purposes of the law if he or she is unable to participate in a
clinical trial for the requested experimental treatment.
Oklahoma, for example, requires that the patient either be
“unable to participate in a clinical trial for the terminal illness
within one hundred . . . miles of the patient’s home address, or
not been accepted to the clinical trial within one . . . week of the
completion of the clinical trial application process[.]”86 By
requiring that patients first attempt to access the drug through
the clinical trial process, these additional requirements mitigate
the concern that trials will suffer if Right to Try laws are
Oklahoma’s
distance
limitation
remains
legalized.87
compassionate to terminally ill patients that are unable to travel
far distances from their homes or hospitals.88 Oklahoma’s timing
limitation recognizes that many terminally ill patients do not
have the time to wait for an acceptance to a clinical trial.89
The second additional requirement, adopted by three
states,90 requires a physician to ascertain that the experimental
drug’s potential risks to the patient do not outweigh its potential
benefits to the patient.91 The FDA’s expanded access program
similarly requires a determination by the FDA that the “patient
benefit justifies the potential risks of the treatment use and [the]
potential risks are not unreasonable in the context of the
disease . . . .”92
Such risk-benefit analyses compel physicians to look at their
patients’ situations analytically and objectively, allowing the
physician to make a more informed, and ideally less emotional,
decision for his or her patient. Although the risks and benefits of

86

Id. Maine includes a similar provision, stating that an “eligible patient” is one
who has “[n]ot been accepted into a clinical trial within one week of completion of
the clinical trial application process[.]” ME. STAT. tit. 602-A, § 2671(1)(c) (2016).
87
See WEISFELD, supra note 41 and accompanying text for an explanation of the
argument that clinical trials might suffer as a result of Right to Try legislation.
88
CORIERI, supra note 17, at 11 (stating that many patients “do not live near or
have the ability to travel to a medical facility where [a clinical] trial is being
conducted”).
89
See id.
90
Indiana, Virginia, and Utah.
91
See VA. CODE ANN. § 54.1-3442.2(A)(3) (West 2015) (“The potential benefits of
use of the investigational drug . . . are greater than the potential risks of the use of
the investigational drug . . . .”).
92
FDA Expanded Access to Investigational Drugs, 21 C.F.R. § 312.305(a)(2)
(2016).
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a potential drug to a particular patient are largely
undeterminable at this state, “the physician should make this
determination based on the information about the drug available
to the physician and the physician’s knowledge of the patient’s
clinical situation.”93 This analysis thus ensures that the current
foreseeable risks are no greater than the current foreseeable
benefits, in the patient’s particular circumstance. The patient
should be made aware that they may suffer unanticipated risks,
and that foreseeable benefits are not guaranteed, in his or her
informed consent document.
B.

Manufacturer Protections

All Right to Try laws share one important aspect: it is
entirely the drug manufacturer’s decision whether to make its
investigational drug available to an eligible patient.94 If the
manufacturer, having ultimate control over the drug, chooses not
to participate in the “right to try” process, then the law cannot
achieve its purpose.
Manufacturers are “rational economic actor[s],” whose
purpose is to get their drugs on the market.95 Thus, factors such
as the threat of liability and the FDA’s approval process will
likely deter any voluntary action by a manufacturer.96 Because
Right to Try laws cannot succeed without manufacturer
participation, some states have included provisions to protect
manufacturers from liability and the FDA’s approval process.
The FDA’s Expanded Access program offers no such protections
for manufacturers.
Nineteen states have adopted provisions protecting
manufacturers from liability.97
Generally, such provisions
provide that there is no private cause of action created against a

93
FOOD & DRUG ADMIN., EXPANDED ACCESS TO INVESTIGATIONAL DRUGS FOR
TREATMENT AND USE—QUESTIONS AND ANSWERS 11 (Oct. 2017), https://www.
fda.gov/downloads/drugs/guidances/ucm351261.pdf.
94
James M. Beck, On “Right to Try” Legislation, DRUG & DEVICE LAW (Oct. 23,
2014), https://www.druganddevicelawblog.com/2014/10/on-right-to-try-legislation.ht
ml.
95
Id.
96
Id. (“You won’t induce a manufacturer to participate in a voluntary program
by painting a target on its back.”).
97
Alabama, Arizona, Colorado, Florida, Indiana, Maine, Michigan, Minnesota,
Mississippi, Montana, Nevada, North Carolina, North Dakota, Oklahoma, South
Dakota, Texas, Virginia, and Wyoming.
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manufacturer, or any other person or entity involved in the care
of an eligible patient using an investigational drug, if the
manufacturer or other person or entity is complying with the
statute in good faith and with reasonable care.98
Two states, Indiana and Texas, have adopted slightly edited
versions of this provision, which may ultimately have destructive
effects.99 Both states’ laws provide that there is no cause of
action against a manufacturer, but neither requires that the
manufacturer act in good faith or with reasonable care to invoke
the protection. Critics have expressed concern, echoed by the
FDA, that unregulated manufacturers might take advantage of
desperate patients.100
Umbrella protection generates concern that less scrupulous
manufacturers may negligently, or even willfully, provide a
desperate patient with an unsafe drug. A manufacturer who
knows, or reasonably should know, that its drug is unsafe for
human consumption, may be less prudent when distributing the
drug if it cannot be held liable.
Additionally, a majority of Right to Try laws allow
manufacturers to decide whether and what to charge a patient
for its drug.101 Under all Right to Try laws, a patient’s health
insurance provider is not required to cover costs associated with
an experimental drug.102 Thus, patients may be left with costly
medical bills. Concern follows that “without proper oversight” a
manufacturer could “inflate the cost associated with the
production of the drug and take advantage of” a distressed and

98

See, e.g., COLO. REV. STAT. § 25-45-107 (2014).
IND. CODE ANN. § 16-42-26-5 (West 2015); TEX. HEALTH AND SAFETY CODE
ANN. § 489.054 (West 2015).
100
Senate Hearing, supra note 37 (statement of Peter Lurie, Associate
Commissioner for Public Health Strategy and Analysis, U.S. FDA) (“FDA is
concerned about the ability of unscrupulous individuals to exploit such desperate
patients.”); see also Jonathan Friedlaender, The Proposed Federal “Right-To-Try”
Law is Not the Answer for Critically Ill Patients, HEALTH AFFAIRS (Sept. 27, 2016),
http://www.healthaffairs.org/do/10.1377/hblog20160927.056819/full (“Without safeguards, less scrupulous providers will take advantage.”).
101
See, e.g., MINN. STAT. § 151.375(5) (2015).
102
See, e.g., id. § 151.375(7).
99
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desperate class of people.103
Umbrella protection for
manufacturers, with no requirement that they act with good
faith or reasonable care, makes this concern more realistic.
Some states have taken steps to mitigate this concern.
Arizona, for example, allows a manufacturer to charge only the
out-of-pocket costs expended in providing that particular drug to
that particular patient.104 This is also the approach taken by the
FDA’s Expanded Access program.105 Other states, such as Texas,
prohibit the manufacturer from charging at all.106
In states that do not specify what the manufacturer may
charge, an equality discussion has transpired. If a patient bears
the total cost of an experimental drug, and there is no cap on the
cost, this law in effect is a law for the wealthy.107 The “right” in
right to try is the right to fight to save your life, but that right
would only be available for those who can afford it.108 South
Dakota allows a manufacturer to use its discretion to provide a
drug to an eligible patient without compensation.109 Requiring a
manufacturer to provide a drug removes any financial incentive
for the manufacturer to participate in “right to try”; laws such as
South Dakota’s at least encourage a manufacturer to act when an
eligible patient is unable to afford the drug.
The second factor important in encouraging manufacturers’
voluntary participation is to prohibit the use of adverse events
suffered by right to try patients in the drug’s FDA approval
process.110 Typically, a drug manufacturer’s end goal is to
market its drug to the public. If negative side effects suffered by
a single patient, outside the scope of mandatory clinical trials,
deter achievement of that goal, a manufacturer is less likely to

103
Jessica M. Maxwell, Patients’ Right to Choose; The Right-To-Try Law
Movement, 9 HEALTH L. OUTLOOK 1, 4 (2016), http://scholarship.shu.edu/health-lawoutlook/vol9/iss1/5.
104
ARIZ. REV. STAT. ANN. § 36-1312(B)(1)–(2) (2014).
105
FOOD & DRUG ADMIN., CHARGING FOR INVESTIGATIONAL DRUGS UNDER AN
IND—QUESTIONS AND ANSWERS 7–8 (June 2016), https://www.fda.gov/downloads/
drugs/guidancecomplianceregulatoryinformation/guidances/ucm351264.pdf.
106
TEX. HEALTH AND SAFETY CODE. ANN. § 489.053(c) (2015).
107
Y. Tony Yang et al., “Right-To-Try” Legislation: Progress or Peril?, 33 J.
CLINICAL ONCOLOGY 2597, 2598 (2015) (explaining the issue of “access disparities
because only the wealthy would be able to access” experimental treatments).
108
Id.; see also Joel B. Finkelstein, FDA Clarifies Rules for Getting Experimental
Drugs, 99 J. NAT’L CANCER INST. 584, 585 (2007).
109
H.B. 1080, 90th Leg. Assemb. Sess. (S.D. 2015).
110
Beck, supra note 39.
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voluntarily provide its drug to that patient. While no state Right
to Try law has addressed whether or not a manufacturer must
report adverse events suffered by a patient to the FDA, the
Trickett Wendler Act prevents the FDA from using such side
effects to adversely impact review or approval of the drug.111
Conversely, the FDA’s Expanded Access program requires that
any side effects be reported as part of the drug’s approval
process.112
The FDA has an interest in protecting the public health at
large. If not properly addressed, a negative side effect suffered
by one person could become a negative side effect suffered by
another.113 Thus, while a manufacturer’s voluntary participation
is necessary for a successful Right to Try statute, it remains
critical that the FDA account for all possible side effects of a drug
in that drug’s approval process.114 Further, there may be other
ways to incentivize manufacturer participation without
disrupting our system, such as by offering tax breaks or federal
subsidies for manufacturers that comply;115 or, better yet,
requiring manufacturers to report adverse side effects while
barring the FDA from rejecting a drug on the basis of reports
from terminally ill patients.
C.

Similarities Between Right To Try Laws

While Right to Try laws are permeated with differences, they
also share two notable similarities: (1) the definition of
“experimental drug,” and (2) physical protection.

111
S. 2912, 114th Cong. § 2(b)(2) (2016) (“[T]he outcome of any production,
manufacture, distribution, prescribing, dispensing, possession, or use of” such a
treatment “shall not be used by a Federal agency . . . [to] adversely impact review or
approval of [the treatment].”).
112
21 C.F.R. § 312.305(4)–(5) (2016). The FDA has a responsibility to protect the
public health. Therefore, the FDA has a substantial interest in gathering all
information about the effects of a drug in order to safely make that drug available
for the public. Senate Hearing, supra note 37 (statement of Peter Lurie, Associate
Commissioner for Public Health Strategy and Analysis, U.S. FDA).
113
How FDA Evaluates Regulated Products: Drugs, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last updated
Nov. 16, 2017).
114
Id.
115
Rubin & Matthews, supra note 56, at 11 (“Congress and the FDA can
incentivize manufacturers’ participation in expanded access by offering tax breaks if
the company participates.”).
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First, all Right to Try laws have the same definition for
“experimental drug.” An experimental drug is “a drug, biological
product, or device that has successfully completed phase one of a
clinical trial but has not yet been approved for general use by the
United States food and drug administration and remains under
investigation in a United States food and drug administrationapproved clinical trial.”116
Despite the definition’s wide adoption by state Right to Try
laws, the Trickett Wendler Act, and even the FDA Expanded
Access program, substantial debate remains over whether Phase
One drugs are safe enough for Right to Try purposes.117 By their
definition, Phase One drugs are not considered safe and
effective.118 Phase One trials are conducted on only about twenty
to eighty participants with the purpose of gathering preliminary
information about the drug’s dosage and acute side effects.119
Most of the drug’s safety data is not gathered until Phase Three
studies, which are conducted on hundreds, sometimes thousands,
of patients.120 Additionally, about eighty-six percent of drugs
that move beyond Phase One “prove to be less effective than”
drugs already on the market.121 Nonetheless, legislators have
accepted Phase One as the threshold for Right to Try laws
nationwide.

116

See, e.g., COLO. REV. STAT. § 25-45-103(2) (2014).
See ‘Right to Try’ Laws Make Safety, Efficacy Secondary to Speedy Access,
SCIENCEDAILY (May 19, 2016), https://www.sciencedaily.com/releases/2016/05/1605
19121110.htm (arguing that Right to Try laws make safety secondary to speedy
access); see also Finkelstein, supra note 108 (arguing that asking for access to
experimental drugs is like “asking the government to sanction the sale of toxic
placebos . . . to say those should be sold to [terminal patients] is just irresponsible”).
But see Frequently Asked Questions, RIGHT TO TRY, http://righttotry.org/faq/ (last
visited Dec. 27, 2017) (arguing that experimental drugs that have passed Phase One
testing are no different than the treatments currently available to patients who are
lucky enough to be accepted into clinical trials).
118
See The Drug Development Process, Step 3: Clinical Research, supra note 42
(FDA explains its three-phase approval process).
119
Id.
120
Id. (pre-phase three studies might not have detected less common side
effects).
121
Jeff Schriber et al., Doctors: Prop. 303 Isn’t in Patients’ Best Interests, ARIZ.
REPUBLIC (Oct. 14, 2014, 3:20 PM), https://www.azcentral.com/story/opinion/op-ed/2
014/10/14/no-prop-303-right-to-try/17270791/.
117
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At their core, Right to Try laws are intended to serve the
terminally ill. It is estimated that the entire drug approval
process, on average, takes between eight to twelve years.122
Terminally ill patients, therefore, may die while waiting for a
drug to come to market or to pass on to a higher phase.123
Terminal patients are often ineligible from participating in a
clinical trial for a variety of reasons, such as age, gender, medical
history, or current medical status.124 With death imminent,
patient advocates argue that risky but potentially beneficial
treatment is better than inaction.125
Second, all Right to Try laws offer some form of protection
for physicians who prescribe, advise, dispense, administer, or are
otherwise involved in the care of an eligible patient using an
experimental drug.126 No law requires that a physician partake
in the process; that decision is solely within the discretion of the
physician.127 However, if a physician chooses to participate and
acts with reasonable care, he or she is protected from liability
and his or her medical license is protected from any form of
reprimand.128 This is an important feature of Right to Try laws
because it allows physicians to act in the best interest of their
patients without fear of being penalized. It also encourages
voluntary participation from physicians.
III. A MODEL CONGRESSIONAL RIGHT TO TRY STATUTE
Despite the inconsistencies among state Right to Try laws,
the Trickett Wendler Act is a meager six sentences.129 While
there is power behind those six sentences, there is not enough
clarity. The Trickett Wendler Act is extremely deferential to
state Right to Try laws in areas where there is no consensus.130
122
Martin S. Lipsky & Lisa K. Sharp, From Idea to Market: The Drug Approval
Process, 14 J. AM. BOARD FAM. MED. 362, 364 (2001).
123
Rubin & Matthews, supra note 56, at 4.
124
Roswell Park Cancer Institute, What Are Eligibility Criteria, and Why Are
They Important?, https://www.roswellpark.org/clinical-trials/eligibility-criteria (last
visited Dec. 27, 2017).
125
Julie Turkewitz, Patients Seek ‘Right to Try’ New Drugs, N.Y. TIMES (Jan. 10,
2015), http://www.nytimes.com/2015/01/11/us/patients-seek-right-to-try-new-drugs.
html.
126
E.g., ALA. CODE §§ 22-5D-6, 22-5D-10 (2015).
127
Id. § 22-5D-7(b) (2015).
128
Id. §§ 22-5D-6, 22-5D-10 (2015).
129
See Trickett Wendler Right to Try Act of 2016, S. 2912, 114th Cong. (2016).
130
Id.
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If America truly wants terminal patients to have the right to try,
Congress must provide clearer guidelines. The model legislation
outlined in the following four Sections is not meant to be
exclusive, but delineates the minimum that should be included in
a congressional Right to Try statute.
A.

Eligibility Requirements

First, a list of eligibility requirements is necessary. At
minimum, that list should include the following seven
requirements: (1) The patient has a terminal illness, attested to
by his or her physician and a consulting physician; (2) The
patient has considered all other currently approved treatment
options; (3) The patient has received a recommendation from his
or her physician for the experimental treatment sought; (4) The
patient has given written, informed consent for the treatment;
(5) The patient is unable to participate in a clinical trial within
one-hundred miles of the patient’s home, or has not been
accepted into a clinical trial within one week of applying; (6) The
patient’s physician has determined that the potential risks of
using the experimental drug do not outweigh the potential
benefits of using the experimental drug, and that the risks are
not unreasonable in the context of the patient’s condition; and
(7) The patient has documentation from his or her physician that
he or she meets all of the eligibility requirements.
Requirements number three and seven are standard,
straightforward requirements. The patient’s physician must
recommend, or prescribe, the experimental treatment being
sought by the patient, and the patient must have documentation
certified by his or her physician that he or she meets all of the
eligibility requirements. These two requirements ensure that a
patient is acting under the recommendation of a doctor, and not
on his or her own whim to access new medication.
Requirement number one should instruct that the patient be
“terminally ill” as attested to by the patient’s physician and a
secondary physician. Often, treating physicians have long-term
relationships with patients that may, even unintentionally, cloud
their decision making.131 The second physician’s opinion will

131

Although physicians should act objectively and in the best interests of their
patients, there is the possibility that a physician’s personal feelings towards
herpatient will unconsciously direct her medical decisions.
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(1) ensure that the patient is “terminally ill” for purposes of the
law and (2) safeguard against overly compassionate treating
physicians who may be unable to evaluate the situation
objectively.132
Eligibility requirement number two, that the patient has
considered all other currently approved options, is another
safeguard for the safety of the patient. Emphasis remains on
access being the patient’s last viable option.
Requirement number four, that the patient has provided
written, informed consent, ensures that a patient understands
the risks of experimenting with an investigational treatment
outside the scope of a controlled clinical trial. Bringing a new life
to the notion of patient autonomy, the right to try movement
argues that it should be the patient’s, not the government’s,
decision whether to try an investigational drug.133 A patient
cannot competently make such a decision without being fully
informed about the treatment. That argument is heightened in a
right to try situation where the risks are greater and the outlook
drearier.
A federal statute should additionally include a specific
definition of “written, informed consent,” highlighting what must
be included in the informed consent document.134 This ensures
that all eligible patients receive enough information to make an
informed decision.
Requirement number five mandates that the patient be
unable to participate in a clinical trial within one-hundred miles
of his or her home, or has not been accepted into the clinical trial
within one week of applying. This requirement counteracts the
fear that Right to Try laws will undermine the clinical trial
process by requiring that patients first volunteer to participate in
a clinical trial before turning to investigational treatment.
Additionally, this reinforces the law’s intent to be a last resort
option.
By setting distance and time limitations, this
requirement also takes into account that patients are often
ineligible or unable to participate in a clinical trial.
Requirement number six requires the patient’s physician to
undertake a risk-benefit analysis.
The physician must
132
This is a common requirement of death by dignity laws throughout the
country. See, e.g., CAL. HEALTH & SAFETY CODE § 443.6 (2015).
133
Maxwell, supra note 103, at 3.
134
See supra notes 60–61 and accompanying text.

FINAL_DELGROSSO

2017]

3/25/2018 7:33 PM

FIGHTING FOR YOUR LIFE IN AMERICA

765

confidently affirm that the experimental drugs’ potential risks do
not outweigh its potential benefits to the patient, and that the
risks are not unnecessary in the context of the patient’s
condition. The physician should perform such an analysis using
information about the drug available to him and his knowledge of
the patient’s clinical condition. This protects the patient from
taking unreasonable risks.
B.

Definitions of Unsettled Terms

Second, clear definitions should be provided for unsettled
terms. “Terminally ill” should be defined as a progressive
disease or medical condition that is not considered by a treating
physician to be reversible even with administration of current
FDA approved and available treatments, and that, without lifesustaining treatment, will likely result in death within one year,
or a state of permanent unconsciousness from which recovery is
unlikely.
This definition does four important things. First, it removes
the requirement that the disease or condition entail “significant
functional impairment.” There is no agreed upon definition for
this term, and the same disease or condition often manifests
itself differently in one person from the next.135 By removing the
phrase altogether, the statute avoids identifying which terminal
patients are suffering from significant functional impairment and
which are not.
Second, it requires that the condition not be reversible even
with the administration of currently approved treatments. This
statute must be a last resort option. If a patient has a chance at
survival through another approved, and arguably safer, line of
treatment, the patient should take that option.
Third, the definition requires that death will likely occur
within one year. Once again, this statute is a last resort option.
There is very minimal knowledge about the safety of Phase One
drugs. If a patient can reasonably wait for further safety testing
of a drug, they should. This definition does not state that death
is certain to occur within one year, only that it is likely to occur
135
EXPANDED ACCESS TO INVESTIGATIONAL DRUGS FOR TREATMENT AND USE—
QUESTIONS AND ANSWERS, supra note 93, at 12 (explaining that one individual may
be denied for expanded access while another individual is approved expanded access
for the same drug because there may be significant differences in the clinical
presentation of the disease or condition among the two patients).
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within one year. If there is medical reason to believe that the
patient has a year or less to live, that should be sufficient to
trigger this statute.
C.

Additional Provisions

Third, a congressional statute should also address the
protection and incentives available to induce a manufacturer’s
voluntary participation.
Manufacturer participation should
remain voluntary because a federal statute forcing participation
in distributing a drug that has not yet been legally approved
undermines the FDA’s approval process.
To encourage voluntary participation, a provision should be
included protecting manufacturers who act in good faith with
reasonable care from liability. Manufacturers are more likely to
comply with a statute that does not threaten liability. The
requirement that the manufacturer act with good faith and
reasonable care to invoke the protection at the same time protects
patients from unscrupulous manufacturers.
Although a federal statute should encourage manufacturer
participation, the statute should not prevent the reporting of
adverse side effects suffered by a right to try patient to the FDA.
While this may deter voluntary participation from manufacturers
who have an interest in getting their drugs to the market, the
FDA’s interest in providing the public with safe drugs, and the
public’s interest in consuming the safest drugs possible, is
stronger. If a drug induces a certain side effect, even a rare side
effect, the FDA should account for that side effect in the drug’s
approval process.
A federal statute should also include a provision specifying
what a manufacturer may charge for its drug. Such a provision
should leave the decision of whether to charge with the
manufacturer, but limit any charges to the out-of-pocket costs
related to the drug’s distribution to a specific patient. Allowing a
manufacturer to charge may serve as an additional incentive for
participation.
But, by capping the amount chargeable,
unscrupulous manufacturers will be unable to over-charge a
patient. Additionally, limiting the amount chargeable makes it
more realistic that economically disadvantaged patients will be
able to benefit from the law. This should not be a law for only
wealthy patients.
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D. Reconciling State Laws
Lastly, the noted similarities among state Right to Try laws
should be adopted into a federal Right to Try statute. First, the
definition of an “experimental drug,” which has been adopted in
state statutes across the country, should also be adopted in the
federal statute. An “experimental drug” is defined as “a drug,
biological product, or device that has successfully completed
phase one of a clinical trial but has not yet been approved for
general use by the United States food and drug administration
and remains under investigation in a United States food and
drug administration-approved clinical trial.”136 Currently, this is
the strongest definition available, allowing the earliest access for
terminal patients possible while still providing some safetycheck.
Second, physicians’ participation should remain voluntary.
To encourage participation, a federal statute should ensure that
physicians, if complying with the statute in good faith and with
reasonable care, be granted protection from liability and from
reprimands to their medical licenses. Physician participation is
critical for the success of a federal statute and for the safety of
patients. Under the watch of a physician, a patient can more
safely be prescribed and administered experimental drugs.
CONCLUSION
Right to Try laws are highly controversial, and for good
reason. Notwithstanding the debate between proponents and
opponents, the right to try movement has only gained momentum
since its inception, and will likely continue on that path. If such
a law is to be adopted federally, the law must be drafted to
protect the safety of terminal patients and the safety of the
public health as a whole. Achieving this balance is possible.
A federal statute must not rely on new, untested state laws,
as the Trickett Wendler Act does. By combining the strongest
state policies, the FDA’s view, and the arguments of proponents
and opponents, a federal statute can reach its potential, creating
a successful and unquestionable “right to try” for terminal
patients.

136

See, e.g., COLO. REV. STAT. § 25-45-103(2) (2014).

